Carisbamate: Difference between revisions
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Carisbamate''' (YKP 509) is an experimental [[anticonvulsant]] drug under development by [[Johnson & Johnson Pharmaceutical Research and Development]]. In 1998, the compound was in-licensed from SK Pharma (currently SK Holding), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partical seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase 3 clinical trial for the treatment of partial seizures. As of September, 2007, the trial had completed enrollment, but the blind had not been broken. Assuming the the phase III trial demonstrates positive results consistent with the phase II study, the company expects to file for registration in 2008. Its [[mechanism of action]] is unknown <ref>{{cite journal |author=Rogawski MA |title=Diverse mechanisms of antiepileptic drugs in the development pipeline |journal=Epilepsy Res |volume=69 |issue=3 |pages=273-294 |year=2006 |PMID=16621450}}</ref> <ref>{{cite journal |author=Novak GP, Kelley M, Zannikos P, Klein B |title=Carisbamate (RWJ-333369) |journal=Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |volume=4 |issue=1 |pages=106-109 |year=2007 |PMID=17199023}}</ref>. | '''Carisbamate''' (YKP 509) is an experimental [[anticonvulsant]] drug under development by [[Johnson & Johnson Pharmaceutical Research and Development]]. In 1998, the compound was in-licensed from SK Pharma (currently SK Holding), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partical seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase 3 clinical trial for the treatment of partial seizures. As of September, 2007, the trial had completed enrollment, but the blind had not been broken. Assuming the the phase III trial demonstrates positive results consistent with the phase II study, the company expects to file for registration in 2008. Its [[mechanism of action]] is unknown <ref>{{cite journal |author=Rogawski MA |title=Diverse mechanisms of antiepileptic drugs in the development pipeline |journal=Epilepsy Res |volume=69 |issue=3 |pages=273-294 |year=2006 |PMID=16621450}}</ref> <ref>{{cite journal |author=Novak GP, Kelley M, Zannikos P, Klein B |title=Carisbamate (RWJ-333369) |journal=Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |volume=4 |issue=1 |pages=106-109 |year=2007 |PMID=17199023}}</ref>. | ||
| Line 35: | Line 39: | ||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
[[Category:Carbamates]] | [[Category:Carbamates]] | ||
[[Category:Drug]] | |||
{{pharma-stub}} | {{pharma-stub}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
Latest revision as of 20:18, 8 April 2015
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C9H10ClNO3 |
| Molar mass | 215.633 g/mol |
|
WikiDoc Resources for Carisbamate |
|
Articles |
|---|
|
Most recent articles on Carisbamate Most cited articles on Carisbamate |
|
Media |
|
Powerpoint slides on Carisbamate |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Carisbamate at Clinical Trials.gov Clinical Trials on Carisbamate at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Carisbamate
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Carisbamate Discussion groups on Carisbamate Patient Handouts on Carisbamate Directions to Hospitals Treating Carisbamate Risk calculators and risk factors for Carisbamate
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Carisbamate |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Carisbamate (YKP 509) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Pharma (currently SK Holding), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partical seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase 3 clinical trial for the treatment of partial seizures. As of September, 2007, the trial had completed enrollment, but the blind had not been broken. Assuming the the phase III trial demonstrates positive results consistent with the phase II study, the company expects to file for registration in 2008. Its mechanism of action is unknown [1] [2].
References
- ↑ Rogawski MA (2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–294. PMID 16621450.
- ↑ Novak GP, Kelley M, Zannikos P, Klein B (2007). "Carisbamate (RWJ-333369)". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 4 (1): 106–109. PMID 17199023.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Anticonvulsants
- Carbamates
- Drug